| 1 | Prader-willi syndrome | Enrichment | HERC2, MAGEL2, MKRN3, NDN, OCA2, SNRPN | 10.49 |
| 2 | Schaaf-yang syndrome | Enrichment | MAGEL2, NDN, OCA2, SNRPN | 9.35 |
| 3 | Angelman syndrome due to imprinting defect in 15q11-q13 | Enrichment | ATP10A, SNRPN, UBE3A | 7.02 |
| 4 | Normosmic congenital hypogonadotropic hypogonadism | Enrichment | GNRH1, KISS1, NHLH2, TACR3 | 5.91 |
| 5 | Oculocutaneous albinism | Enrichment | OCA2, SLC45A2, TYR | 5.48 |
| 6 | Lip and oral cavity carcinoma | Enrichment | CDKN2A, RB1, TP53 | 4.69 |
| 7 | Skin/hair/eye pigmentation, variation in, 1 | Enrichment | HERC2, OCA2 | 4.67 |
| 8 | Angelman syndrome due to maternal 15q11q13 deletion | Enrichment | OCA2, UBE3A | 4.67 |
| 9 | Melanoma, cutaneous malignant 1 | Enrichment | CDK4, CDKN2A, CDKN2B | 4.21 |
| 10 | Osteogenic sarcoma | Enrichment | RB1, TP53 | 4.20 |
| 11 | Squamous cell carcinoma | Enrichment | RB1, TP53 | 4.20 |
| 12 | Bone osteosarcoma | Enrichment | RB1, TP53 | 4.20 |
| 13 | Body mass index quantitative trait locus 11 | Enrichment | BDNF, GHRL, PCSK1, POMC | 4.08 |
| 14 | Small cell cancer of the lung | Enrichment | RB1, TP53 | 3.90 |
| 15 | Genetic central precocious puberty in male | Enrichment | KISS1, MKRN3 | 3.90 |
| 16 | Chromosome 15q11.2 deletion syndrome | Enrichment | NIPA1, NIPA2 | 3.68 |
| 17 | Angelman syndrome | Enrichment | GABRG3, UBE3A | 3.50 |
| 18 | Li-fraumeni syndrome | Enrichment | CDKN2A, TP53 | 3.50 |
| 19 | Adrenocortical carcinoma | Enrichment | CDKN2A, TP53 | 3.50 |
| 20 | Albinism | Enrichment | OCA2, TYR | 3.50 |
| 21 | Bladder cancer | Enrichment | CDKN2A, RB1, TP53 | 3.49 |
| 22 | Multiple endocrine neoplasia, type i | Enrichment | CDKN2B, CDKN2C | 3.36 |
| 23 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | Enrichment | CDKN2A, TP53 | 3.36 |
| 24 | Leukemia, chronic lymphocytic | Enrichment | CCND1, TP53 | 3.03 |
| 25 | Gastric cancer | Enrichment | CDK4, CDKN2A, TP53 | 2.99 |
| 26 | Chromosome 1p36 deletion syndrome | Enrichment | GABRD, PRKCZ | 2.80 |
| 27 | Lung cancer susceptibility 3 | Enrichment | RB1, TP53 | 2.73 |
| 28 | Myeloma, multiple | Enrichment | CCND1, CDKN2C, TP53 | 2.65 |
| 29 | Inherited cancer-predisposing syndrome | Enrichment | CDK4, CDKN2A, RB1, TP53 | 2.48 |
| 30 | Split-hand/foot malformation 1 with sensorineural hearing loss, autosomal recessive | Enrichment | DLX5 | 2.33 |
| 31 | Albinism, oculocutaneous, type iv | Enrichment | SLC45A2 | 2.33 |
| 32 | Albinism, oculocutaneous, type ib | Enrichment | TYR | 2.33 |
| 33 | Melanoma, cutaneous malignant 3 | Enrichment | CDK4 | 2.33 |
| 34 | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3 | Enrichment | CCND2 | 2.33 |
| 35 | Microcephaly 12, primary, autosomal recessive | Enrichment | CDK6 | 2.33 |
| 36 | Bardet-biedl syndrome 4 | Enrichment | BBS4 | 2.33 |
| 37 | Skin/hair/eye pigmentation, variation in, 5 | Enrichment | SLC45A2 | 2.33 |
| 38 | Skin/hair/eye pigmentation, variation in, 3 | Enrichment | TYR | 2.33 |
| 39 | Hypogonadotropic hypogonadism 27 without anosmia | Enrichment | NHLH2 | 2.33 |
| 40 | Developmental and epileptic encephalopathy 79 | Enrichment | GABRA5 | 2.33 |
| 41 | Bone marrow failure syndrome 5 | Enrichment | TP53 | 2.33 |
| 42 | Papilloma of choroid plexus | Enrichment | TP53 | 2.33 |
| 43 | Basal cell carcinoma 7 | Enrichment | TP53 | 2.33 |
| 44 | Autism 19 | Enrichment | EIF4E | 2.33 |
| 45 | Anaplastic thyroid carcinoma | Enrichment | TP53 | 2.33 |
| 46 | Epilepsy, idiopathic generalized 10 | Enrichment | GABRD | 2.33 |
| 47 | Hypogonadotropic hypogonadism 13 with or without anosmia | Enrichment | KISS1 | 2.33 |
| 48 | Intellectual developmental disorder, autosomal recessive 38 | Enrichment | HERC2 | 2.33 |
| 49 | Hypogonadotropic hypogonadism 12 with or without anosmia | Enrichment | GNRH1 | 2.33 |
| 50 | Epilepsy, childhood absence 5 | Enrichment | GABRB3 | 2.33 |
| 51 | Ductal carcinoma in situ | Enrichment | TP53 | 2.33 |
| 52 | Developmental and epileptic encephalopathy 43 | Enrichment | GABRB3 | 2.33 |
| 53 | Thyroid gland undifferentiated carcinoma | Enrichment | TP53 | 2.33 |
| 54 | Skin melanoma | Enrichment | SLC45A2 | 2.33 |
| 55 | Trilateral retinoblastoma | Enrichment | RB1 | 2.33 |
| 56 | Small-cell carcinoma of the ovary of hypercalcemic type | Enrichment | TP53 | 2.33 |
| 57 | Cdkn2a cancer predisposition | Enrichment | CDKN2A | 2.33 |
| 58 | Diffuse pediatric-type high-grade glioma, h3-wildtype and idh-wildtype | Enrichment | TP53 | 2.33 |
| 59 | Choroid plexus cancer | Enrichment | TP53 | 2.33 |
| 60 | Minimal pigment oculocutaneous albinism type 1 | Enrichment | TYR | 2.33 |
| 61 | Xq27.3q28 duplication syndrome | Enrichment | FMR1 | 2.33 |
| 62 | Split hand-foot malformation 1 with sensorineural hearing loss | Enrichment | DLX5 | 2.33 |
| 63 | 15q11q13 microduplication syndrome | Enrichment | UBE3A | 2.33 |
| 64 | Pleomorphic xanthoastrocytoma | Enrichment | TP53 | 2.33 |
| 65 | Hypopigmentation of the skin | Enrichment | TYR | 2.33 |
| 66 | Lung oat cell carcinoma | Enrichment | RB1 | 2.33 |
| 67 | Pancreatic cancer | Enrichment | CDKN2A, TP53 | 2.23 |
| 68 | Melanoma-astrocytoma syndrome | Enrichment | CDKN2A | 2.03 |
| 69 | Adrenocortical carcinoma, hereditary | Enrichment | TP53 | 2.03 |
| 70 | Spastic paraplegia 6, autosomal dominant | Enrichment | NIPA1 | 2.03 |
| 71 | Cervical cancer | Enrichment | TP53 | 2.03 |
| 72 | Melanoma, cutaneous malignant 2 | Enrichment | CDKN2A | 2.03 |
| 73 | Orofacial cleft 5 | Enrichment | MSX1 | 2.03 |
| 74 | Hypogonadotropic hypogonadism 11 with or without anosmia | Enrichment | TACR3 | 2.03 |
| 75 | Chromosome 13q14 deletion syndrome | Enrichment | RB1 | 2.03 |
| 76 | Maturity-onset diabetes of the young, type 10 | Enrichment | INS | 2.03 |
| 77 | Witkop syndrome | Enrichment | MSX1 | 2.03 |
| 78 | Lymphoma, hodgkin, classic | Enrichment | TP53 | 2.03 |
| 79 | Albinism, oculocutaneous, type ia | Enrichment | TYR | 2.03 |
| 80 | Hyperproinsulinemia | Enrichment | INS | 2.03 |
| 81 | Melanoma, cutaneous malignant 8 | Enrichment | TYR | 2.03 |
| 82 | Melanoma-pancreatic cancer syndrome | Enrichment | CDKN2A | 2.03 |
| 83 | Congenital fibrosarcoma | Enrichment | TP53 | 2.03 |
| 84 | Li-fraumeni syndrome 1 | Enrichment | TP53 | 2.03 |
| 85 | Sarcoma | Enrichment | TP53 | 2.03 |
| 86 | Diabetes mellitus, permanent neonatal, 4 | Enrichment | INS | 2.03 |
| 87 | Hypophosphatasia | Enrichment | OCA2 | 2.03 |
| 88 | Cervix carcinoma | Enrichment | TP53 | 2.03 |
| 89 | Hodgkin's lymphoma | Enrichment | TP53 | 2.03 |
| 90 | Familial retinoblastoma | Enrichment | RB1 | 2.03 |
| 91 | Pleomorphic rhabdomyosarcoma | Enrichment | TP53 | 2.03 |
| 92 | Ovarian cancer | Enrichment | CDKN2A, RB1, TP53 | 1.94 |
| 93 | Type 1 diabetes mellitus 2 | Enrichment | INS | 1.86 |
| 94 | Retinoblastoma | Enrichment | RB1 | 1.86 |
| 95 | Hypophosphatasia, infantile | Enrichment | OCA2 | 1.86 |
| 96 | Obesity, early-onset, with adrenal insufficiency and red hair | Enrichment | POMC | 1.86 |
| 97 | Body mass index quantitative trait locus 12 | Enrichment | PCSK1 | 1.86 |
| 98 | Nasopharyngeal carcinoma | Enrichment | TP53 | 1.86 |
| 99 | Woolly hair, autosomal recessive 3 | Enrichment | RB1 | 1.86 |
| 100 | Proprotein convertase 1/3 deficiency | Enrichment | PCSK1 | 1.86 |
| 101 | Hypotrichosis 8 | Enrichment | RB1 | 1.86 |
| 102 | Dedifferentiated liposarcoma | Enrichment | CDK4 | 1.86 |
| 103 | Precocious puberty, central, 2 | Enrichment | MKRN3 | 1.86 |
| 104 | Atypical teratoid rhabdoid tumor | Enrichment | TP53 | 1.86 |
| 105 | Anaplastic astrocytoma | Enrichment | TP53 | 1.86 |
| 106 | Adenocarcinoma | Enrichment | TP53 | 1.86 |
| 107 | Well-differentiated liposarcoma | Enrichment | CDK4 | 1.86 |
| 108 | Obesity due to pro-opiomelanocortin deficiency | Enrichment | POMC | 1.86 |
| 109 | Thyroid cancer, nonmedullary, 1 | Enrichment | TP53 | 1.73 |
| 110 | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1 | Enrichment | CCND2 | 1.73 |
| 111 | Fragile x tremor/ataxia syndrome | Enrichment | FMR1 | 1.73 |
| 112 | Lynch syndrome 4 | Enrichment | RB1 | 1.73 |
| 113 | Mantle cell lymphoma | Enrichment | CCND1 | 1.73 |
| 114 | Fragile x-associated tremor/ataxia syndrome | Enrichment | FMR1 | 1.73 |
| 115 | Neonatal diabetes mellitus | Enrichment | INS | 1.73 |
| 116 | Lung sarcomatoid carcinoma | Enrichment | TP53 | 1.73 |
| 117 | Embryonal rhabdomyosarcoma | Enrichment | TP53 | 1.73 |
| 118 | Cleft lip and alveolus | Enrichment | MSX1 | 1.73 |
| 119 | Von hippel-lindau syndrome | Enrichment | CCND1 | 1.64 |
| 120 | Albinism, oculocutaneous, type ii | Enrichment | OCA2 | 1.64 |
| 121 | Premature ovarian failure 1 | Enrichment | FMR1 | 1.64 |
| 122 | Fragile x syndrome | Enrichment | FMR1 | 1.64 |
| 123 | Rhabdomyosarcoma 2 | Enrichment | TP53 | 1.64 |
| 124 | Lymphoma | Enrichment | TP53 | 1.64 |
| 125 | Acute megakaryocytic leukemia | Enrichment | TP53 | 1.64 |
| 126 | Cleft upper lip | Enrichment | MSX1 | 1.64 |
| 127 | Split-hand/foot malformation 1 | Enrichment | DLX5 | 1.56 |
| 128 | Wilms tumor, aniridia, genitourinary anomalies, and impaired intellectual development syndrome | Enrichment | BDNF | 1.56 |
| 129 | Type 1 diabetes mellitus | Enrichment | INS | 1.56 |
| 130 | Epilepsy, childhood absence 1 | Enrichment | GABRB3 | 1.56 |
| 131 | Albinism, ocular, type i | Enrichment | TYR | 1.56 |
| 132 | Breast adenocarcinoma | Enrichment | TP53 | 1.56 |
| 133 | Lung squamous cell carcinoma | Enrichment | CDKN2A | 1.56 |
| 134 | Childhood absence epilepsy | Enrichment | GABRB3 | 1.56 |
| 135 | Esophageal cancer | Enrichment | TP53 | 1.49 |
| 136 | Squamous cell carcinoma, head and neck | Enrichment | TP53 | 1.49 |
| 137 | Waardenburg syndrome, type 2e | Enrichment | TYR | 1.49 |
| 138 | Neuropathy, hereditary sensory and autonomic, type v | Enrichment | NGF | 1.49 |
| 139 | Essential thrombocythemia | Enrichment | TP53 | 1.49 |
| 140 | Gallbladder cancer | Enrichment | TP53 | 1.49 |
| 141 | Glioma susceptibility 1 | Enrichment | TP53 | 1.44 |
| 142 | Lymphoma, non-hodgkin, familial | Enrichment | TP53 | 1.44 |
| 143 | Lennox-gastaut syndrome | Enrichment | GABRB3 | 1.44 |
| 144 | Permanent neonatal diabetes mellitus | Enrichment | INS | 1.44 |
| 145 | Isolated split hand-split foot malformation | Enrichment | DLX5 | 1.44 |
| 146 | Tooth agenesis, selective, 1 | Enrichment | MSX1 | 1.39 |
| 147 | Adult hepatocellular carcinoma | Enrichment | TP53 | 1.39 |
| 148 | Hypogonadotropic hypogonadism | Enrichment | TACR3 | 1.39 |
| 149 | Congenital central hypoventilation syndrome | Enrichment | BDNF | 1.39 |
| 150 | Primary hyperaldosteronism | Enrichment | TP53 | 1.39 |
| 151 | Optic nerve disease | Enrichment | TYR | 1.34 |
| 152 | Melanoma | Enrichment | CDKN2A | 1.34 |
| 153 | Familial colorectal cancer | Enrichment | TP53 | 1.34 |
| 154 | Breast cancer | Enrichment | CDKN2B, TP53 | 1.32 |
| 155 | Epilepsy, myoclonic juvenile | Enrichment | GABRD | 1.30 |
| 156 | Epilepsy, idiopathic generalized | Enrichment | GABRD | 1.30 |
| 157 | Leukemia, acute lymphoblastic | Enrichment | CDKN2A | 1.30 |
| 158 | Myelodysplastic syndrome | Enrichment | TP53 | 1.30 |
| 159 | Diabetes mellitus | Enrichment | INS | 1.30 |
| 160 | Bardet-biedl syndrome 1 | Enrichment | BBS4 | 1.23 |
| 161 | Colorectal cancer | Enrichment | CCND1, TP53 | 1.21 |
| 162 | Hypogonadotropic hypogonadism 7 with or without anosmia | Enrichment | TACR3 | 1.20 |
| 163 | Generalized epilepsy with febrile seizures plus | Enrichment | GABRD | 1.20 |
| 164 | Cleft lip/palate | Enrichment | MSX1 | 1.20 |
| 165 | Myopia | Enrichment | TYR | 1.17 |
| 166 | Hydrocephalus, congenital, 1 | Enrichment | MAGEL2 | 1.14 |
| 167 | Rhabdomyosarcoma | Enrichment | TP53 | 1.14 |
| 168 | Gliosarcoma | Enrichment | TP53 | 1.14 |
| 169 | Giant cell glioblastoma | Enrichment | TP53 | 1.12 |
| 170 | Diffuse large b-cell lymphoma | Enrichment | TP53 | 1.07 |
| 171 | Maturity-onset diabetes of the young | Enrichment | INS | 1.05 |
| 172 | Hepatoblastoma | Enrichment | TP53 | 1.03 |
| 173 | Hepatocellular carcinoma | Enrichment | TP53 | 1.01 |
| 174 | Tooth agenesis | Enrichment | MSX1 | 1.01 |
| 175 | Skin disease | Enrichment | TYR | 1.01 |
| 176 | Diamond-blackfan anemia 1 | Enrichment | TP53 | 0.99 |
| 177 | Kallmann syndrome | Enrichment | TACR3 | 0.99 |
| 178 | Precursor t-cell acute lymphoblastic leukemia | Enrichment | CDKN2A | 0.99 |
| 179 | Strabismus | Enrichment | TYR | 0.93 |
| 180 | Prostate cancer | Enrichment | TP53 | 0.90 |
| 181 | Differentiated thyroid carcinoma | Enrichment | PCM1 | 0.90 |
| 182 | Primary autosomal recessive microcephaly | Enrichment | CDK6 | 0.86 |
| 183 | Peripheral nervous system disease | Enrichment | NGF | 0.86 |
| 184 | Neuropathy | Enrichment | NGF | 0.86 |
| 185 | Eye disease | Enrichment | TYR | 0.82 |
| 186 | Diamond-blackfan anemia | Enrichment | TP53 | 0.81 |
| 187 | Fetal akinesia deformation sequence 1 | Enrichment | MAGEL2 | 0.80 |
| 188 | Leukemia, acute myeloid | Enrichment | TP53 | 0.77 |
| 189 | Epilepsy | Enrichment | GABRB3 | 0.77 |
| 190 | Bardet-biedl syndrome | Enrichment | BBS4 | 0.75 |
| 191 | Hereditary spastic paraplegia | Enrichment | NIPA1 | 0.75 |
| 192 | Hereditary breast carcinoma | Enrichment | TP53 | 0.73 |
| 193 | Hereditary breast ovarian cancer syndrome | Enrichment | TP53 | 0.65 |
| 194 | Undetermined early-onset epileptic encephalopathy | Enrichment | GABRA5 | 0.64 |
| 195 | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Enrichment | NIPA1 | 0.63 |
| 196 | Autism spectrum disorder | Enrichment | TACR3 | 0.40 |
| 197 | Retinitis pigmentosa | Enrichment | BBS4 | 0.20 |
| 198 | Hereditary retinal dystrophy | Enrichment | BBS4 | 0.13 |
| 199 | Fundus dystrophy | Enrichment | BBS4 | 0.13 |